– Whether patients with hypercholesterolemia in primary and 2nd-ary prevention are at the higher risk of severe course of the Covid-19 disease and why, and how to optimally prevent this and reduce the risk of COVID-19 complications,

– How to optimally treat patients with ACS? What we should do in order to achieve the goal of the therapy <70 mg/dL for high risk, <55 form very high risk and <40 for extremely high risk?

– Whether we should start with fixed combination/polypills with statins and ezetimibe and add PCSK9 inhibitors as quickly as possible (during hospitalization)? What might be the role of the well-prepared discharge letter? 

– What about the safety of the lipid-lowering therapy with Covid-19 drugs, including antiviral drugs (remdesivir), antiretroviral drugs (lopinavir/ritonavir), macrolides (mainly azithromycin), anti-malaria (chloroquine and hydroxychloroquine) and anti-rheumatoid (tocilizumab),

– What is the current status of the reimbursement of PCSK9 inhibitors for ACS in different CEE countries? When we might expect we will be able to treat our patients effectively?

Webinar Międzynarodowego Towarzystwa Lipidologicznego

Rejestracja: https://ilep.eu/registration/?fbclid=IwAR1V87P5sRjplWhiHGKEiRf55G7-RuZePq2sZG2H8qUSlGODQYi4umkr_Ng

– What are the best experiences on effective diagnosis of FH patients? Do we really need systemic solutions? 

– How optimally manage with severe hypercholesterolemia patients, including FH patients, in Covid-19 pandemic based on the new ILEP and FH Europe recommendations,

– New data on drugs with the possible applications in FH patients (recent PCSK9 studies, recent data on fixed combination of statins and ezetimibe, bempedoic acid),

– The status of reimbursement of PCSK9 inhibitors in Europe countries and whether pandemic might be used to extend the existing reimbursement programs; 

– FH patients at very high and extremely high risk – how to effectively achieve <55 and <40 mg/dl? 

Experts:

Prof. Maciej Banach Polish Mother’s Memorial Hospital – Research Institute, Lodz (Poland)	Prof. Michal Vrablik Charles University of Prague, Prague (Czechia)	Prof. Ivan Pećin University Hospital Centre Zagreb (Croatia)	Prof. Branislav Vohnout Slovak Medical University in Bratislava, Bratislava (Slovakia)

Prof. Maciej Banach Polish Mother’s Memorial Hospital – Research Institute, Lodz (Poland)	Prof. Željko Reiner University Hospital Centre Zagreb, Zagreb (Croatia)	Prof. Dan Gaita Institute of Cardiovascular Medicine, Timisoara (Romania)	Prof. Daniel Pella Pavol Jozef Safarik University (UPJS), Kosice (Slovakia)

– Actual epidemiological situation on the prevalence and effectiveness of therapy of hypercholesterolemia in CEE based on the most recent data (including NCDRisC and GBD analyses and EuroASPIRE V recent analyses),

– Risk stratification and diagnosis of severe hypercholesterolemia based on new ESC/EAS 2019 guidelines, and how to do it correctly in the time of coronavirus infection, 

– Primary prevention patients at CVD risk – critical, underweight group of patients with dyslipidemias; 

– What is the extremely high CVD risk of patients based on guidelines and the recent PCSK9 inhibitors analyses, as well as based on recent national guidelines, including e.g. PoLA/PSLD guidelines 2020;

– Lack of effectiveness of our therapy (non-adherence, statin intolerance, drug-to-drug interactions, including COVID-19 therapy, physical inertia, anti-statin movements);

– Are there any additional benefits of statins and PCSK9 inhibitors in the fighting against coronavirus infection? PCSK9 inhibitors and their anti-inflammatory role. Statins as the antiviral drugs? 

webinar z Laureatem Nagrody Nobla Aaronem Ciechanover'em na temat roli nauki w społeczeństwie. Wydarzenie odbędzie się w środę 17 czerwca o godz. 09:00. Rejestracja:
https://bit. ly/2XOtDbv


Nobel Media, in partnership with AstraZeneca are pleased to invite you to an exclusive webinar with Nobel Laureate Aaron Ciechanover. The session will be an interview and audience Q&A on the topic of ‘Are we in the midst of a knowledge crisis? The role of science in society’.

This will take place on Wednesday 17 June from 09:00 – 10:15. An invitation is attached, and please confirm your attendance by registering at: https://bit.ly/2XOtDbv. Please register early as spaces may be limited.